This release contains 1,001 approved relationships.
Added entries:
- (FDA) KMT2A translocations and sensitivity to revumenib for adult and pediatric patients 1 year and older with acute leukemia, entered as acute myeloid leukemia and acute lymphoid leukemia.
- (FDA) NRG1 fusions and sensitivity to zenocutuzumab-zbco for adult patients with non-small cell lung cancer and pancreatic adenocarcinoma.